Novavax Inks Vaccine Deals In Japan, India


Every human life if precious and sacred and saving one is like the saving of the whole of humanity. (Al Quran 5:32/33)


Fuji Mountain in Japan. The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Source: Yahoo Finance

Novavax announced a partnership with Takeda Pharmaceutical to sell up to 250 million doses of NVX‑CoV2373, its COVID-19 vaccine candidate, a year in Japan.

As part of the partnership, Novavax (NVAX) will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan. In exchange, Novavax will receive payments based on the achievement of certain development and commercial milestones, as well as a portion of vaccine proceeds.

NVX-CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes the company’s proprietary Matrix M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Takeda (TAK) said it will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer and infrastructure and to scale-up of manufacturing.

“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX-CoV2373,” said Novavax CEO Stanley C. Erck. “We look forward to collaborating with Takeda to rapidly develop, produce and commercialize the vaccine in Japan.”

In addition, Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX-CoV2373 in Japan.

Last week, Novavax disclosed that Phase 1 data from its Phase 1/2 randomized, placebo-controlled trial of NVX-CoV2373, showed “robust” virus neutralizing antibody responses. The early stage trial demonstrated that the experimental vaccine was generally well-tolerated and had a reassuring safety profile.

Separately, the biotech company announced the signing of a license and supply agreement with the Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVX-CoV2373 in low- and middle-income countries (LMIC) and throughout India.

For LMICs and India, Novavax and SIIPL are partnering on clinical development, co-formulation, filling and finishing and commercialization of NVX-CoV2373. As part of the partnership, Novavax expects to supply a minimum of 1 billion doses of the potential vaccine for India and low- and middle-income countries.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters


Coronavirus Vaccine Tracker – The New York Times

Categories: The Muslim Times, Vaccine

1 reply

  1. Goldman Sachs has grown more optimistic about the arrival date for a coronavirus vaccine, causing it to upgrade its expetations for economic growth and cut its projection for the unemployment rate.

    The firm sees “at least one” vaccine approved by the end of 2020 and hitting the market for widespread distribution by the second quarter of 2012, progress that will boost consumer spending and generate stronger GDP readings and employment next year.

    In its revised forecast, Goldman still sees the jobless rate, currently at 10.1%, falling to 9% by the end of this year. However, it is projecting a decline to 6.5% by the end of 2021, which is half a percentage point less than its previous foreccast.

    On GDP, the economists also are leaving their 2020 estimates unchanged, with annualized gains of 25.2% in the third quarter and 8% in Q4.

    However for the full year of 2021, it sees GDP growing 6.2% on an annual average basis vs. its previous estimate of 5.6% and ahead of the Federal Reserve’s projection of 5%. The firm’s expectations are now for quarterly increases of 10%, 8%, 4% and 3% in 2021, against previous respective estimates of 8%, 6.5%, 5% and 4%.

    One reason for the optimism is that because the U.S. has struggled so much to contain the pandemic, it has increased the urgency for a vaccine.

    “The vaccine outlook has since become clearer and more positive, and the economic benefits for the US appear particularly large due to its leadership in the vaccine race and worse virus control,” Goldman economist Joseph Briggs wrote. “As a result, we now expect that at least one vaccine will be approved this fall with widespread distribution and positive growth effects felt in the first half of 2021.”

    There have been just over 5 million Covid-19 cases in the U.S., with about 163,000 deaths attributed to the virus, according to Johns Hopkins University.

    The U.S. government has funded three potential vaccines for Phase 3 trials. The competing companies are Moderna, AstraZeneca, which has partnered with the University of Oxford, and Pfizer and BioNTech. However there are some 42 companies that have vaccines in development, according to the Regulatory Affairs Professionals Society.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.